The cellular neurobiology of depression
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Major depressive disorders, long considered to be of neurochemical origin, have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity that putatively mediates depressive symptoms (Drevets et al, 2002a), or by enhancing the expression of neurotrophic factors that protect medial network function from the effects of repeated stress (Manji et al, 2001).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Manji et al, 2001
In the citing paper
“Somatic antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity which putatively mediates depressive symptoms (Drevets et al. 2002a) and the expression of neurotrophic/neuroprotective factors that preserve the function of the MPFC (Manji et al. 2001).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Manji et al. 2001
In the citing paper
“Depression is often associated with elevated HPA axis activity and increased levels of glucocorticoids, as well as disruption of negative feedback mechanisms21–23.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [22]
Citations
Cites
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369 · cited 1×
“However, the demonstration that neurogenesis occurs in the adult human brain into senescenc”
BackgroundThe Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332 · cited 1×
“Modest changes in this signaling cascade or in the levels of the Bcl-2 family of proteins (potentially due to genetic, illness or insult-related factors) could therefore profoundly affect cellular viabilit”
BackgroundGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“It is thus not altogether surprising that the Global Burden of Disease Study has identified MDDs among the leading causes of disability worldwide, and as illnesses likely to represent an increasingly greater health, societal and economic problem in the coming year”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Current research is examining the potential efficacy of antagonists of corticotropin-releasing factor (CRF), antiglucocorticoids and direct and indirect glutamate antagonist”
BackgroundSelf-citationChronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“These studies demonstrate that chronic administration of different classes of antidepressants increases the proliferation and survival of new neuron”
BackgroundPsychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 1×
“Moreover, lithium also inhibits the activity of glycogen synthase kinase 3β (GSK-3β”
BackgroundThe Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129 · cited 1×
“have demonstrated that an important pathway involved in cell survival and plasticity, the cAMP–CREB cascade, is up-regulated by antidepressant treatmen”
BackgroundTHE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION
Kessler, R. C. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.191 · Cited by 2,111 · cited 1×
“Thus, although MDDs undoubtedly have a strong genetic basis, severe stressors have been associated with a substantial increase in risk for the onset of MDDs in susceptible individuals ( Table 3”
Background
Research works printed but not linked: 4
- Garlow, S.J., Musselman, D.L. & Nemeroff C.B. The Neurochemistry of Mood Disorders clinical studies. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 348–364 (Oxford Press, New York, 1999).
- Drevets, W.C., Gadde, K. & Krishnan, R. Neuroimaging studies of depression. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 394–418 (Oxford Press, New York, 1999).
- LeDoux, J.E. Emotion. in Handbook of Physiology—The Nervous System, Vol. V. (eds. Mills, J., Mountcastle, V.B., Plum, F. & Geiger, S.R.) 373–417 (Williams & Wilkins, Baltimore, 1987).
- Manji, H.K. et al. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. in Bipolar Medications: Mechanisms of Action. (eds. Manji, H.K., Bowden, C.L. & Belmaker, R.H.) 129–177 (American Psychiatric Press, Washington, DC, 2000).
Cited by
Items 201–300 of 1,000
Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than “depressive”
Zörner, B., Wolfer, D. P., Brandis, D., Kretz, O., Zacher, C., Madani, R., Kadow, I. C. G., Lipp, H., Klein, R., Henn, F. A., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00418-9 · Cited by 164
“Thus, this mouse strain should not be regarded as a genetic mouse model for depression as expected by the neurotrophin hypothesis (Altar 1999; Duman et al 1997; Manji et al 2001; Nestler et al 2002; Vaidya and Duman 2001; Wong and Licinio 2001).”
BackgroundDefining the Neural Circuitry of Depression: Toward a New Nosology With Therapeutic Implications
Mayberg, H. S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.013 · Cited by 158
Bacq, A., Balasse, L., Biała, G., Guiard, B. P., Gardier, A. M., Schinkel, A. H., Louis, F., Vialou, V., Martres, M., Chevarin, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.87 · Cited by 153
Par-4 Links Dopamine Signaling and Depression
Park, S. K., Nguyen, M. D., Fischer, A., Luke, M. P.-S., Affar, E. B., Dieffenbach, P. B., Tseng, H.-C., Shi, Y., & Tsai, L. (2005) · Cell · doi:10.1016/j.cell.2005.05.031 · Cited by 157
“…are usually significantly delayed, it is now believed that an adaptation of downstream events, including changes in gene expression and/or modification of other neurotransmitter systems, due to chronic treatment underlies their antidepressant efficacy (Manji et al., 2001; Wong and Licinio, 2001).”
BackgroundJiang, X., Xing, G., Yang, C., Verma, A. M., Zhang, L., & Li, H. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.71 · Cited by 152
“The pathophysiological alterations in synaptic transmission within the BLA, thus, are closely associated with multiple stress and anxiety disorders (”
BackgroundJay, T. M., Rocher, C., Hotte, M., Naudon, L., Gurden, H., & Spedding, M. (2004) · Neurotoxicity Research · doi:10.1007/bf03033225 · Cited by 141
“Recent studies have demonstrated that molecular events known to regulate synaptic plasticity are also involved in the action of psychotropic drugs used to treat depression, bipolar disorder and schizophrenia (Duman et al., 1997; Dowlatshahi et al., 1998; Manji et al., 2001; 2003).”
BackgroundReversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens
Alexander, B., Warner-Schmidt, J., Eriksson, T. M., Tamminga, C., Arango-Lievano, M., Ghose, S., Vernov, M., Stavarache, M., Musatov, S., Flajolet, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001079 · Cited by 140
“Abnormalities of the serotonergic system underlie an array of psychiatric pathologies, including depression, anxiety, alcoholism, and impulsive behavior (1).”
Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder
Shaltiel, G., CHEN, G., & Manji, H. K. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.07.005 · Cited by 139
Self-citationRab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunities
Agola, J., Jim, P., Ward, H., BasuRay, S., & Wandinger-Ness, A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01724.x · Cited by 139
“Valproic acid is therapeutically used as a mood stabilizer for the treatment of bipolar disorder (85).”
BackgroundMcKernan, D. P., Dinan, T. G., & Cryan, J. F. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.006 · Cited by 147
“For this reason, a better understanding of the pathophysiology of depression and chronic stress and also detailed studies into the cellular effects of antidepressants are needed (Manji et al., 2001; Krishnan and Nestler, 2008).”
BackgroundBipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers
Manji, H. K., Moore, G. J., & Chen, G. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.41.s107 · Cited by 140
Self-citationResidual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Czeh, B., Simon, M., van der Hart, M. G., Schmelting, B., Hesselink, M. B., & Fuchs, E. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300581 · Cited by 136
“…number of clinical and preclinical studies indicate that major depressive disorders may be associated with an impairment of structural plasticity and cellular resilience, and that antidepressant medications may act by correcting this dysfunction (Duman et al, 1999; Manji et al, 2000, 2001, 2003).”
Marco, E. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136
“In accordance, a similar decrease in hippocampal BDNF has been reported in animals exposed to CMS, probably indicating diminished hippocampal neurogenesis (Manji et al., 2001; Nestler et al., 2002).”
BackgroundMerke, D. P., Fields, J. D., Keil, M. F., Vaituzis, A. C., Chrousos, G. P., & Giedd, J. N. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021730 · Cited by 137
“Changes in amygdala function have been implicated in the pathophysiology of adult anxiety and depressive disorders (48, 58, 59).”
BackgroundSchmitz, C., Rhodes, M. E., Bludau, M., Kaplan, S., Ong, P., Ueffing, I., Vehoff, J., Korr, H., & Frye, C. A. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001118 · Cited by 140
Salehpour, F., Farajdokht, F., Cassano, P., Sadigh‐Eteghad, S., Erfani, M., Hamblin, M. R., Salimi, M. M., Karimi, P., Rasta, S. H., & Mahmoudi, J. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.010 · Cited by 153
Essential function of HIPK2 in TGFβ-dependent survival of midbrain dopamine neurons
Zhang, J., Pho, V., Bonasera, S. J., Holtzman, J., Tang, A. T., Hellmuth, J. M., Tang, S., Janak, P. H., Tecott, L. H., & Huang, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1816 · Cited by 147
“The selective loss of DA neurons, or perturbations to the neural circuits established by DA neurons, such as the nigrostriatal and mesolimbic pathways, have been implicated in several neurodegenerative conditions, including Parkinson's diseas”
BackgroundGonadal steroid regulation of mood: The lessons of premenstrual syndrome☆
Rubinow, D. R., & SCHMIDT, P. (2006) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2006.02.003 · Cited by 194
“Stress decreases BDNF in animal models [8,25], and both Bcl-2 and BDNF are increased by antidepressants and mood stabilizers [38,49,50], eVects also seen after exposure to estradiol [14,72].”
BackgroundMolecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Role of the endocannabinoid system in depression and suicide
Vinod, K. Y., & Hungund, B. L. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.08.006 · Cited by 145
“Neuroimaging and post-mortem studies of patients with major depression have identified neurophysiological abnormalities in multiple areas of the prefrontal cortex and its linked brain regions [ 1 ,2].”
BackgroundInfluentialEffects of music therapy on depression compared with psychotherapy
Castillo-Pérez, S., Gómez-Pérez, V., Velasco, M. C., Pérez‐Campos, E., & Mayoral, M. Á. (2010) · The Arts in Psychotherapy · doi:10.1016/j.aip.2010.07.001 · Cited by 168
The Fibroblast Growth Factor System and Mood Disorders
Turner, C. A., Akil, H., Watson, S. J., & Evans, S. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.026 · Cited by 131
Takebayashi, M., Hisaoka, K., Nishida, A., Tsuchioka, M., Miyoshi, I., Kozuru, T., Hikasa, S., Okamoto, Y., Shinno, H., Morinobu, S., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006085 · Cited by 132
“Recent imaging and biochemical studies in mood disorders have revealed a morphological reduction of several brain areas (Manji et al., 2001; Ongur et al., 1998; Rajkowska, 2002) and alternations of multiple neurotrophic/growth factor systems (Evans et al., 2004; Hock et al., 2000; Shimizu et al.,…”
BackgroundEinat, H., YUAN, P., & Manji, H. K. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.06.012 · Cited by 132
Self-citationInvolvement of Na+, K+-ATPase and Endogenous Digitalis-Like Compounds in Depressive Disorders
Goldstein, I., Levy, T., Galili, D. S., Ovadia, H., Yirmiya, R., Rosen, H., & Lichtstein, D. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.021 · Cited by 132
Leonard, B. E. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.018 · Cited by 129
“More recently, attention has been directed to the role of neuropeptides, such as corticotrophin releasing factor (CRF) and brain derived neurotrophic factor (BDNF) (Duman et al., 2001; Manji et al., 2001).”
Antidepressants act directly on astrocytes: Evidences and functional consequences
Czéh, B., & Benedetto, B. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.017 · Cited by 143
“Over the years, this hypothesis has been refined, but it has become evident that factors beyond monoamine deficiency or imbalance in the respective neurotransmitter systems must be taken into account (Manji et al., 2001; Nestler et al., 2002; Castr en, 2005; Krishnan and Nestler, 2008, 2010).”
BackgroundMerke, D. P., Giedd, J. N., Keil, M. F., Mehlinger, S. L., Wiggs, E. A., Holzer, S., Rawson, E., Vaituzis, A. C., Stratakis, C. A., & Chrousos, G. P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2488 · Cited by 128
Molecular aspects of depression: A review from neurobiology to treatment
Villas Boas, G. R., Boerngen de Lacerda, R., Paes, M. M., Gubert, P., Almeida, W. L. D. C., Rescia, V. C., de Carvalho, P. M. G., de Carvalho, A. A. V., & Oesterreich, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.024 · Cited by 128
“In these regions, both metabolism and volume are reduced, whereas hippocampal atrophy occurs with the progression of the depressive syndrome (Gould et al., 2000; Manji et al., 2001).”
BackgroundWiles, N. J., Peters, T. J., Leon, D. A., & Lewis, G. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.1.21 · Cited by 126
Chronic social defeat reduces myelination in the mouse medial prefrontal cortex
Lehmann, M. L., Weigel, T. K., Elkahloun, A. G., & Herkenham, M. (2017) · Scientific Reports · doi:10.1038/srep46548 · Cited by 127
Carvacrol: From Ancient Flavoring to Neuromodulatory Agent
Zotti, M., Colaianna, M., Morgese, M. G., Tucci, P., Schiavone, S., Avato, P., & Trabace, L. (2013) · Molecules · doi:10.3390/molecules18066161 · Cited by 139
“In this regard, it is worthy to note that the monoamine hypothesis of depression is based on the deficiency of more than one monoamine [40] and most of the antidepressants exert their primary biochemical effects by regulating synaptic concentrations of several neurotransmitters, among which a pivotal role is certainly…”
BackgroundChen, J., Zhao, L., Liu, Y., Fan, S., & Xie, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.028 · Cited by 146
McEwen, B. S., & Olié, J. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001648 · Cited by 145
Blood, A. J., Iosifescu, D. V., Makris, N., Perlis, R. H., Kennedy, D. N., Dougherty, D. D., Kim, B. W., Lee, M. J., Wu, S., Lee, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013945 · Cited by 126
“Animal models of MDD strongly support this thesis and have hypothesized dopaminergic midbrain nuclei and the medial forebrain bundle (MFB) to be involved with the illness [7,25]; these subcortical regions are at the core of the animal literature that first identified reward circuitry [26,27,28,29,30].”
BackgroundThe cholinergic system and depression
Dagytė, G., den Boer, J. A., & Trentani, A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.023 · Cited by 138
“This spectrum of sympoms is thought to arise from the complex interaction between ultiple genetic and environmental factors [6].”
BackgroundSigma receptors: Potential targets for a new class of antidepressant drug
Fishback, J. A., Robson, M. J., Xu, Y.-T., & Matsumoto, R. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.003 · Cited by 125
The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers
Chen, G., & Manji, H. K. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218604.63463.cd · Cited by 127
Self-citationKoponen, E., Rantamäki, T., Voikar, V., Saarelainen, T., MacDonald, E., & Castrén, E. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-8468-z · Cited by 125
“plasticity as potential neuronal mechanisms of the antidepressant action (Manji et al., 2001; Castrén, 2005).”
BackgroundHubbs-Tait, L., Nation, J. R., Krebs, N. F., & Bellinger, D. C. (2005) · Psychological Science in the Public Interest · doi:10.1111/j.1529-1006.2005.00024.x · Cited by 125
Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats
Parise, E. M., Alcantara, L. F., Warren, B. L., Wright, K. N., Hadad, R., Sial, O. K., Kroeck, K. G., Iñiguez, S. D., & Bolaños-Guzmán, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.027 · Cited by 125
Gene Expression Profiling of Depression and Suicide in Human Prefrontal Cortex
Sibille, E. L., Arango, V., Galfalvy, H., Pavlidis, P., Erraji-Benchekroun, L., Ellis, S., & Mann, J. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300335 · Cited by 142
“More recently a hypothesis for a cellular neurobiology of depression and antidepressant action emphasized the modulation of neuroplasticity and cellular resilience (Duman et al, 1997; Manji et al, 2001).”
BackgroundGreen, M. K., Rani, C. S. S., Joshi, A., Soto-Piña, A. E., Martinez, P. A., Frazer, A., Strong, R., & Morilak, D. A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.041 · Cited by 124
How could stress lead to major depressive disorder?
Richter-Levin, G., & Xu, L. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.04.001 · Cited by 120
Jeong, M. R., Hashimoto, R., Senatorov, V. V., Fujimaki, K., Ren, M., Lee, M. S., & Chuang, D.-M. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00350-8 · Cited by 126
Electroconvulsive Seizure Treatment Increases Cell Proliferation in Rat Frontal Cortex
Madsen, T. M., Yeh, D. D., Valentine, G. W., & Duman, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300565 · Cited by 139
“In addition to alterations in the morphology of the hippocampus, brain imaging and post-mortem studies have reported atrophy and cell loss in the frontal cortex of depressed patients (Duman et al, 2001; Manji et al, 2001; Nestler et al, 2002).”
BackgroundCastrén, E., & Rantamäki, T. (2010) · CNS Drugs · doi:10.2165/11530010-000000000-00000 · Cited by 123
Zhang, A., Leow, A., Ajilore, O., Lamar, M., Yang, S., Joseph, J., Medina, J., Zhan, L., & Kumar, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.279 · Cited by 121
“Neuropathological analyses in depressed subjects have shown abnormal reduction in glial cells in the subgenual prefrontal cortex, orbital cortex, dorsal anterolateral prefrontal, and amygdala (”
BackgroundStress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4
Sailaja, B. S., Cohen-Carmon, D., Zimmerman, G., Soreq, H., & Meshorer, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209990110 · Cited by 121
“Current antidepressants are not very effective in curing stress/depression, and symptoms reappear in many patients after the discontinuation of treatment (29, 30).”
BackgroundEngel, S. R., Creson, T. K., Hao, Y., Shen, Y., Maeng, S., Nekrasova, T., Landreth, G. E., Manji, H. K., & Chen, G. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002135 · Cited by 135
Self-citationGene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder
Kang, H. J., Adams, D. H., Simen, A., Simen, B. B., Rajkowska, G., Stockmeier, C. A., Overholser, J. C., Meltzer, H. Y., Jurjus, G. J., Konick, L. C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4083-07.2007 · Cited by 119
“Brain imaging studies demonstrate altered blood flow, metabolism, and morphology in limbic structures of depressed patients (Drevets, 2001; Manji et al., 2001; Nestler et al., 2002a; WarnerSchmidt and Duman, 2006).”
BackgroundPsychological Factors in Asthma
Van Lieshout, R. J., & MacQueen, G. (2008) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-4-1-12 · Cited by 118
Carrier, N., Saland, S. K., Duclot, F., He, H., Mercer, R., & Kabbaj, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.024 · Cited by 116
Sex differences in learning deficits induced by prenatal stress in juvenile rats
Gué, M., Bravard, A., Meunier, J., Veyrier, R., Gaillet, S., Récasens, M., & Maurice, T. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00250-x · Cited by 120
The Dopamine D2 Receptor: New Surprises from an Old Friend
Bonci, A., & Hopf, F. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.015 · Cited by 115
“It is clear that a number of neurochemical systems can be altered during depression and might contribute to the clinical syndromes observed in humans (Manji et al., 2001; Nestler et al., 2002).”
BackgroundDepression: What We can Learn from Postmortem Studies
Rajkowska, G. (2003) · The Neuroscientist · doi:10.1177/1073858403252773 · Cited by 115
Cognition in mania and depression
TAVARES, J. V. T., DREVETS, W. C., & SAHAKIAN, B. J. (2003) · Psychological Medicine · doi:10.1017/s0033291703008432 · Cited by 113
Self-citationSocial vs. environmental stress models of depression from a behavioural and neurochemical approach
Vénzala, E., Garcia‐García, Á. L., Elizalde, N., & Tordera, R. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.010 · Cited by 132
“However, it should be acknowledged that this hypothesis is mainly based on the well known clinical effect of selective serotonin reuptake inhibitors (Schildkraut et al., 1965; Manji et al., 2001).”
Anti‐inflammatory, antiapoptotic, and antioxidant activity of fluoxetine
Caiaffo, V., Oliveira, B. D. R., de Sá, F. B., & Evêncio Neto, J. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.231 · Cited by 111
“, fluoxetine) and stress regulate neurotrophic factors, such as CREB and BDNF, which are involved in cell survival pathways and control the expression of proapoptotic and antiapoptotic proteins (Manji et al. 2001).”
BackgroundStructural and functional models of depression: from sub‐types to substrates
Malhi, G. S., Parker, G. B., & Greenwood, J. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00475.x · Cited by 111
Comparison of human solute carriers
Schlessinger, A., Matsson, P., Shima, J. E., Pieper, U., Yee, S. W., Kelly, L., Apeltsin, L., Stroud, R. M., Ferrin, T. E., Giacomini, K. M., et al. (2010) · Protein Science · doi:10.1002/pro.320 · Cited by 114
“Many antidepressants selectively inhibit the SLC6A4 (SERT) serotonin transporter, which is responsible for serotonin reuptake from synaptic spaces.(32,33) In addition, solute carriers can modulate drug levels within the body by regulating their absorption, distribution, metabolism, and elimination (ADME).”
BackgroundDepression in Women with Spontaneous 46, XX Primary Ovarian Insufficiency
Schmidt, P. J., Luff, J. A., Haq, N., Vanderhoof, V. H., Koziol, D. E., Calis, K. A., Rubinow, D. R., & Nelson, L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0613 · Cited by 117
“and neurodegeneration in specific brain regions (47), and”
BackgroundAnimal models for bipolar disorder: from bedside to the cage
Beyer, D. K. E., & Freund, N. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0104-6 · Cited by 125
“The glutamatergic system plays a critical role in the regulation of synaptic plasticity (D’Sa and Duman 2002; Manji et al. 2001).”
BackgroundA therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
Witkin, J. M., Tzavara, E. T., Davis, R. J., Li, X., & Nomikos, G. G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.10.006 · Cited by 119
Alves, C. R. R., Merege Filho, C. A. A., Benatti, F. B., Brucki, S., Pereira, R. M. R., de Sá Pinto, A. L., Lima, F. R., Roschel, H., & Gualano, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076301 · Cited by 109
“In fact, changes in brain energy metabolism, neuronal plasticity, and cellular resiliency are associated with the pathogenesis of depressive disorders [20,22,42–45].”
BackgroundVollmayr, B., & Henn, F. A. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00086-0 · Cited by 117
Go, H. S., Kim, K. C., Choi, C. S., Jeon, S. J., Kwon, K. J., Han, S., Lee, J., Cheong, J. H., Ryu, J. H., Kim, C., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.028 · Cited by 119
David, D. J., Wang, J., Samuels, B. A., Rainer, Q., David, I., Gardier, A. M., & Hen, R. (2010) · The Neuroscientist · doi:10.1177/1073858409360281 · Cited by 108
Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
dos Santos, É. R. Q., Maia, J. G. S., Fontes-Júnior, E. A., & Maia, C. D. S. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210920094504 · Cited by 118
Colla, M., Schubert, F., Bubner, M., Heidenreich, J. O., Bajbouj, M., Seifert, F., Luborzewski, A., Heuser, I., & Kronenberg, G. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.26 · Cited by 106
Allen, P. J., D'Anci, K. E., Kanarek, R. B., & Renshaw, P. F. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.160 · Cited by 95
“Changes in brain energy metabolism, neuronal plasticity, and cellular resiliency are associated with the pathogenesis of depressive disorders (Gabbay et al , 2007; Iosifescu et al, 2008; Volz et al , 1998; for review, see Fuchs et al , 2004; Kalia, 2005; Manji et al , 2001; McEwen, 2005).”
The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like Behavior
Du, J., Creson, T. K., Wu, L.-J., Ren, M., Gray, N. A., Falke, C., Wei, Y., Wang, Y., Blumenthal, R., Machado-Vieira, R., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3080-07.2008 · Cited by 107
“Historically, the brain systems that have received the greatest attention in neurobiological studies of mood disorders were the monoaminergic neurotransmitter systems, which are extensively distributed throughout the network of limbic, striatal, hippocampal, and prefrontal cortical neuronal circuits and are thought to…”
BackgroundSelf-citationCytokines as a stressor: implications for depressive illness
Anisman, H., Hayley, S., Turrin, N., & Merali, Z. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003097 · Cited by 106
“Stimulation of these cAMP and MAPkinase-dependent pathways can also induce the anti-apoptotic factor, bcl-2, which has been suggested to have beneficial actions in depressive disorders (Chen et al., 2000;Manji et al., 2001), just as it has a neuroprotective role in neurodegenerative states (Guillin et al.”
BackgroundIñiguez, S. D., Aubry, A., Riggs, L. M., Alipio, J. B., Zanca, R. M., Flores-Ramirez, F. J., Hernandez, M. A., Nieto, S. J., Musheyev, D., & Serrano, P. A. (2016) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.07.001 · Cited by 105
“This suggests that AMPA receptor stabilization may underlie the therapeutic efficacy of antidepressants that involve monoaminergic- and glutamatergic-related signaling (Berton and Nestler, 2006; Manji et al., 2001; Skolnick et al., 2009).”
BackgroundNeurotrophins as Mediators of Drug Effects on Mood, Addiction, and Neuroprotection
Ċastrén, E. (2004) · Molecular Neurobiology · doi:10.1385/mn:29:3:289 · Cited by 119
Isserles, M., Rosenberg, O., Dannon, P., Levkovitz, Y., Kotler, M., Deutsch, F., Lerer, B., & Zangen, A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.038 · Cited by 112
“Numerous lines of evidence deriving from different research and clinical methodologies attest that depression involves integrated neural pathways linking select cortical, subcortical, and limbic sites and their related molecular mediators (Manji et al., 2001; Mayberg, 1997; Nemeroff, 2002; Nestler et al., 2002; Vaidya…”
BackgroundKilbourne, A. M., Brar, J. S., Drayer, R. A., Xu, X., & Post, E. P. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.5.412 · Cited by 116
Reduced Hippocampal 5HT1A PET Receptor Binding and Depression in Temporal Lobe Epilepsy
Theodore, W. H., Hasler, G., Giovacchini, G., Kelley, K., Reeves‐Tyer, P., Herscovitch, P., & Drevets, W. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01089.x · Cited by 102
“Structural imaging studies in major depressive disorders without epilepsy have shown a variety of imaging findings, including reduced gray matter volumes in frontal cortex, striatum, and hippocampus (Manji et al., 2001).”
BackgroundSelf-citationMitoma, M., Yoshimura, R., Sugita, A., Umene, W., Hori, H., Nakano, H., Ueda, N., & Nakamura, J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.011 · Cited by 128
Chen, F., Madsen, T. M., Wegener, G., & Nyengaard, J. R. (2010) · Hippocampus · doi:10.1002/hipo.20718 · Cited by 103
“…is largely influenced by neurotrophic factors (McEwen, 2000; Duman, 2002b), and neurotrophic effects of antidepressants could help restore the functional network by inducing neurogenesis, synaptogenesis, and remodelling of synapses (Manji et al., 2001; Duman, 2002b;WarnerSchmidt and Duman, 2006).”
BackgroundEffect of Antidepressants on the Course of Disability Following Stroke
Mikami, K., Jorge, R. E., Adams, H. P., Davis, P. H., Leira, E. C. C., Jang, M., & Robinson, R. G. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31821181b0 · Cited by 115
Neuroplasticity and major depression, the role of modern antidepressant drugs
Serafini, G. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i3.49 · Cited by 103
A review of the relevance and validity of olfactory bulbectomy as a model of depression
Harkin, A., Kelly, J. P., & Leonard, B. E. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00087-2 · Cited by 111
Gabbay, V., Hess, D. A., Liu, S., Babb, J. S., Klein, R. G., & Gonen, O. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06122032 · Cited by 101
“This hypothesis is based on models of major depression that entail impaired neuroplasticity and its collateral consequences of increased membrane turnover and impaired metabolism and neuronal viability (17).”
MethodFunctional Characterization of Alternative Splicing in the C Terminus of L-type CaV1.3 Channels
Tan, B. Z., Jiang, F., Tan, M. Y., Yu, D., Huang, H. Y., Shen, Y., & Soong, T. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.265207 · Cited by 111
Koh, S., Magid, R., Chung, H., Stine, C. D., & Wilson, D. N. (2006) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2006.11.008 · Cited by 103
“The etiology of depression has long been known to involve serotonergic pathways [25], and selective serotonergic reuptake inhibitors (SSRIs) are currently the recommended first-line medication for depression [26].”
BackgroundYan, Z. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:203 · Cited by 100
Sun, Y., Wang, D., Salvadore, G., Hsu, B., Curran, M., Casper, C., Vermeulen, J., Kent, J. M., Singh, J., Drevets, W. C., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.06.014 · Cited by 100
Self-citationFaster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“Finally, various signalling pathways of cellular resilience and apoptosis, have also been implicated in the pathophysiology and treatment of depression (Manji et al., 2001; McKernan et al., 2009).”
BackgroundDetrimental effects of glucocorticoids on neuronal migration during brain development
Fukumoto, K., Morita, T., Mayanagi, T., Tanokashira, D., Yoshida, T., Sakai, A., & Sobue, K. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.60 · Cited by 108
Pralong, É., Magistretti, P., & Stoop, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00017-5 · Cited by 116
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
“Functional and morphological differences between brains of depressed and non-depressed subjects are likely to be derived from distinct molecular and cellular correlates (Manji et al., 2001).”
BackgroundPrins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
“Therefore, to fully understand the pathophysiology of major depression, one has to measure stress- and depression-related changes in in vivo neurotransmitter reuptake or release; (hetero) receptor trafficking, expression and functioning; post-receptor signaling cascades, gene transcription, translation and expression…”
BackgroundSartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
BDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression
Alexopoulos, G. S., Glatt, C. E., Hoptman, M. J., Kanellopoulos, D., Murphy, C. F., Kelly, R. E., Morimoto, S. S., Lim, K. O., & Gunning, F. M. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.02.115 · Cited by 97
“Altered synaptic and structural plasticity has been proposed as one of the mechanisms of depression (Duman, 2002; Manji et al., 2001).”
BackgroundTransdermal Estradiol for Postpartum Depression: A Promising Treatment Option
MOSES-KOLKO, E. L., BERGA, S. L., KALRO, B., SIT, D. K. Y., & WISNER, K. L. (2009) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3181b5a395 · Cited by 98
Navailles, S., Hof, P. R., & Schmauss, C. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21775 · Cited by 97
“…(including persistent behavioral, endocrine and molecular alterations induced by adverse early life events), lower forebrain serotonin levels, and behavioral responsiveness to chronic (but not acute) antidepressant treatment (Manji et al., 2001; Nestler et al., 2002; Belmaker and Agam, 2008).”
Neumeister, A., Young, T. A., & Stastny, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1950-3 · Cited by 106
“Thus, it is believed that dysfunctional 5-HT1A receptors or reduced number of 5-HT1A receptors may increase the risk for neuropathological abnormalities identified in limbic and paralimbic cortical areas in mood and anxiety disorders, such as reduced cortex volume, reduced synaptic proteins, increased neuronal density…”
BackgroundKanner, A. M., Schachter, S. C., Barry, J. J., Hersdorffer, D. C., Mula, M., Trimble, M., Hermann, B. P., Ettinger, A. E., Dunn, D., Caplan, R., et al. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.01.008 · Cited by 108
“When treated with an AD alone, the patient may cycle into the manic phase of the illness [71].”
Background
Metadata
- Authors
- Manji, H. K., Drevets, W. C., & Charney, D. S.
- Affiliations
- National Institutes of Health (US)
- National Institute of Mental Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Medicine
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 541-547
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1509868652
- Cited by
- 1,182
- References
- 66
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 20 · 2023: 21 · 2022: 33 · 2021: 55 · 2020: 29 · 2019: 29 · 2018: 28 · 2017: 30 · 2016: 36 · 2015: 51 · 2014: 50 · 2013: 60 · 2012: 60
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, neurobiology of depression, neuroplasticity, cell survival, signaling pathways
- MeSH terms
- Antidepressive Agents, Cell Survival, Depressive Disorder, Glucocorticoids, Neuronal Plasticity, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.